Science Corporation has raised $400 million in a Series D round, with investors valuing the medical technology start-up at $3.5 billion, according to a person familiar with the deal. The company, founded by former Neuralink president Max Hodak, said it secured the funding in a blog post.
The investors include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech, TechCrunch reported. Hodak founded Science in 2021 to develop technologies for understanding and interacting with the brain.
The company’s first product, PRIMA, is a wearable and implantable chip intended to help people with age-related macular degeneration regain some vision. It is approved in Europe and available in Germany. Science is also testing the device for other conditions: Hodak announced at TechCrunch Disrupt that trials are underway for Stargardt’s disease, another cause of blindness.
Science plans to use the new funding to seek US access for PRIMA through the FDA’s Humanitarian Device Exemption, a pathway for experimental medical devices treating rare conditions. The company has persuaded the FDA that advanced macular degeneration affecting both eyes is uncommon enough to qualify for consideration under the route.
Beyond PRIMA, Science is developing a bio-hybrid sensor that combines cultured neurons with silicon to connect directly to the brain. The company is designing initial human trials with Murat Günel, a Yale neurosurgery professor. Günel told TechCrunch the technology could potentially lead to treatments for Parkinson’s disease and other brain injuries and illnesses.
Comments (0)
No comments yet. Be the first!